MedTrace Logo

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

NCT01403922 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-10-02

No results posted yet for this study

Summary

This is a two part study. Part 1 will determine determine if administration of TC-5214 has an effect on sitting blood pressure in patients with chronic hypertension.

Part 2 will determine any possible interactions between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors).

Conditions

  • Chronic Hypertension

Interventions

DRUG

TC-5214

Tablet oral bid days 1 to 7

DRUG

TC-5214

Tablet oral bid days 8 to 14

Sponsors & Collaborators

Principal Investigators

  • Hans A Eriksson, MD, PhD, MBA · AstraZeneca PharmaceuticalsKvarnbergagatan 12, 15185, Sodertalje, Sweden

  • James Ritter, MD,FRCP FFPM · Quintiles Drug Research Unit at Guy's HospitalQuintiles Limited6 Newcomen StreetLondon SE1 1YR

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01403922 on ClinicalTrials.gov